<a href="https://laohu8.com/S/NAOV">NanoVibronix Inc</a>. Announces Debt Repayment and Preferred Share Conversion Plan Following $10 Million Public Offering
NanoVibronix, Inc., a medical technology company, has announced the pricing of a $10 million public offering involving Series G Convertible Preferred Stock and Warrants. The offering includes approximately 400,000 shares of Preferred Stock and Warrants to purchase up to 4,901,961 shares of common stock. The proceeds from this offering are intended to be used for the redemption of the principal amount of an outstanding debenture and a partial repayment of an outstanding note, alongside general corporate purposes. The transaction is expected to close around May 19, 2025, contingent upon customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoVibronix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-011246), on May 16, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。